JP2023015301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023015301A5 JP2023015301A5 JP2022183022A JP2022183022A JP2023015301A5 JP 2023015301 A5 JP2023015301 A5 JP 2023015301A5 JP 2022183022 A JP2022183022 A JP 2022183022A JP 2022183022 A JP2022183022 A JP 2022183022A JP 2023015301 A5 JP2023015301 A5 JP 2023015301A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- monoclonal antibody
- sequence
- amino acid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218402A JP2025038079A (ja) | 2016-10-20 | 2024-12-13 | 抗ｃｈｉｋｖ抗体およびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306374 | 2016-10-20 | ||
| EP16306374.6 | 2016-10-20 | ||
| PCT/EP2017/076792 WO2018073387A1 (en) | 2016-10-20 | 2017-10-19 | Anti-chikv antibodies and uses thereof |
| JP2019521142A JP7181193B6 (ja) | 2016-10-20 | 2017-10-19 | 抗ｃｈｉｋｖ抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521142A Division JP7181193B6 (ja) | 2016-10-20 | 2017-10-19 | 抗ｃｈｉｋｖ抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218402A Division JP2025038079A (ja) | 2016-10-20 | 2024-12-13 | 抗ｃｈｉｋｖ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023015301A JP2023015301A (ja) | 2023-01-31 |
| JP2023015301A5 true JP2023015301A5 (https=) | 2023-07-12 |
| JP7664212B2 JP7664212B2 (ja) | 2025-04-17 |
Family
ID=57590434
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521142A Active JP7181193B6 (ja) | 2016-10-20 | 2017-10-19 | 抗ｃｈｉｋｖ抗体およびその使用 |
| JP2022183022A Active JP7664212B2 (ja) | 2016-10-20 | 2022-11-16 | 抗ｃｈｉｋｖ抗体およびその使用 |
| JP2024218402A Pending JP2025038079A (ja) | 2016-10-20 | 2024-12-13 | 抗ｃｈｉｋｖ抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521142A Active JP7181193B6 (ja) | 2016-10-20 | 2017-10-19 | 抗ｃｈｉｋｖ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218402A Pending JP2025038079A (ja) | 2016-10-20 | 2024-12-13 | 抗ｃｈｉｋｖ抗体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11286295B2 (https=) |
| EP (1) | EP3529271A1 (https=) |
| JP (3) | JP7181193B6 (https=) |
| CN (2) | CN110088131B (https=) |
| AR (1) | AR109857A1 (https=) |
| CA (1) | CA3040842A1 (https=) |
| EA (1) | EA201990988A1 (https=) |
| IL (2) | IL310834A (https=) |
| MA (1) | MA46562A (https=) |
| TW (2) | TWI778985B (https=) |
| UY (1) | UY37449A (https=) |
| WO (1) | WO2018073387A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41517A (fr) * | 2015-04-14 | 2017-12-19 | Univ Vanderbilt | Neutralisation du virus du chikungunya à médiation par des anticorps |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| EP3735589A2 (en) | 2018-01-05 | 2020-11-11 | Vanderbilt University | Antibody-mediated neutralization of chikungunya virus |
| KR102201261B1 (ko) * | 2019-05-15 | 2021-01-11 | 한국생명공학연구원 | 치쿤구니야 바이러스에 특이적인 단일클론 항체 및 이의 용도 |
| CN114656554B (zh) * | 2022-03-07 | 2023-05-23 | 中山大学 | 基孔肯雅热病毒e2蛋白的纳米抗体及其应用 |
| CN118956771A (zh) * | 2024-04-24 | 2024-11-15 | 华南农业大学 | 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用 |
| KR102830571B1 (ko) * | 2024-12-20 | 2025-07-09 | 대한민국(질병관리청 국립보건연구원장) | 치쿤구니아 바이러스 외피 재조합 단백질을 포함하는 치쿤구니아열 백신 조성물 |
| CN119841940B (zh) * | 2025-03-19 | 2025-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JP2001522241A (ja) | 1997-04-10 | 2001-11-13 | ロイヤル ネザーランズ アカデミー オブ アーツ アンド サイエンシズ | 診断方法および試薬 |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| DK1817340T3 (da) * | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| CA2591665C (en) * | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| CA2545597A1 (en) | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| RU2529951C2 (ru) | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| CA2712298C (en) * | 2008-01-17 | 2015-11-24 | Irm Llc | Improved anti-trkb antibodies |
| KR101589511B1 (ko) | 2008-04-04 | 2016-02-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 치쿤구니야 바이러스 단백질의 공통 서열, 이를 인코딩하는 핵산 분자, 조성물 및 이를 이용하는 방법 |
| EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| CA2889723A1 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| WO2015010125A1 (en) | 2013-07-19 | 2015-01-22 | Integral Molecular, Inc. | Antibodies against chikungunya virus and uses thereof |
| MA41517A (fr) | 2015-04-14 | 2017-12-19 | Univ Vanderbilt | Neutralisation du virus du chikungunya à médiation par des anticorps |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
-
2017
- 2017-10-18 US US15/787,647 patent/US11286295B2/en active Active
- 2017-10-18 TW TW106135643A patent/TWI778985B/zh active
- 2017-10-18 TW TW111134308A patent/TW202300515A/zh unknown
- 2017-10-19 WO PCT/EP2017/076792 patent/WO2018073387A1/en not_active Ceased
- 2017-10-19 EA EA201990988A patent/EA201990988A1/ru unknown
- 2017-10-19 JP JP2019521142A patent/JP7181193B6/ja active Active
- 2017-10-19 IL IL310834A patent/IL310834A/en unknown
- 2017-10-19 MA MA046562A patent/MA46562A/fr unknown
- 2017-10-19 EP EP17794260.4A patent/EP3529271A1/en active Pending
- 2017-10-19 IL IL266082A patent/IL266082B2/en unknown
- 2017-10-19 CA CA3040842A patent/CA3040842A1/en active Pending
- 2017-10-19 CN CN201780078371.3A patent/CN110088131B/zh active Active
- 2017-10-19 CN CN202211721154.0A patent/CN115873106A/zh active Pending
- 2017-10-20 AR ARP170102933A patent/AR109857A1/es unknown
- 2017-10-20 UY UY0001037449A patent/UY37449A/es unknown
-
2022
- 2022-02-16 US US17/672,871 patent/US12227560B2/en active Active
- 2022-11-16 JP JP2022183022A patent/JP7664212B2/ja active Active
-
2024
- 2024-12-13 JP JP2024218402A patent/JP2025038079A/ja active Pending
-
2025
- 2025-01-27 US US19/038,334 patent/US20260001940A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023015301A5 (https=) | ||
| JP2025036561A5 (https=) | ||
| PH12021500002A1 (en) | ANTIBODY-SIRPa ANTIBODY | |
| JP2011528902A5 (https=) | ||
| RU2012118636A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2012504955A5 (https=) | ||
| JP2023071956A5 (https=) | ||
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| RU2007139915A (ru) | Haemophilus influenzae типа в | |
| JP2020500538A5 (https=) | ||
| RU2012112829A (ru) | Анти-gitr-антитела | |
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| RU2018113505A (ru) | Il-8-связывающие антитела и их применения | |
| JP2018512124A5 (https=) | ||
| JP2023093753A5 (https=) | ||
| JP2018514193A5 (https=) | ||
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| AU2019200589A1 (en) | Interferon alpha and omega antibody antagonists | |
| JP2026004299A5 (https=) | ||
| JP2021517459A5 (https=) | ||
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения |